Category Archives: Life Sciences Industry
Relating to the Life Sciences Industry in general
ARCS Australia appoints Commercial Eyes Founder and Managing Director to Board.
ARCS Australia, a leading, membership-based organisation focused on the development and growth of the Australian healthcare sector, has appointed Commercial Eyes Founder and Managing Director, Andrew Carter, to its Board of Directors. With nearly 30 years’ experience in the medicines … Continue reading
Commercial Eyes at PharmAus19
The Commercial Eyes team had the pleasure of joining colleagues, clients, and representatives from across the pharmaceutical industry this week for PharmAus19 at Australia’s Parliament House. PharmAus is an annual event held in Canberra and hosted by Medicines Australia to … Continue reading
Leukaemia Foundation – Raising Awareness of Blood Cancers
September is Blood Cancer Awareness month Through various parts of our business including market access and insights, regulatory services and medical communications, Commercial Eyes works with a number of organisations involved in improving and extending the lives of people living … Continue reading
PHARMAC prepares to take over the procurement of medical devices
Access to medical devices in New Zealand is changing The Therapeutic Products Bill will be published shortly, resulting in PHARMAC assuming responsibility for the procurement and funding of medical devices in addition to their current brief of medicines. This … Continue reading
PHARMAC issues a call for funding applications for medicines for rare disorders
Applications will be accepted until 5pm on the 5th of August 2019 and will be considered by the Rare Disorders Subcommittee at their meeting scheduled for the 24th of September 2019. Eligibility criteria: The medicine must have been approved … Continue reading
Are you ready for the mandatory transition to eCTD for prescription medicines?
In October 2018 the TGA announced the long-awaited timelines for transition to eCTD. A staged implementation has been proposed for prescription medicines to reflect the current industry uptake of the eCTD format. The transition begins with new chemical entity, new … Continue reading
November 2018 PBAC Meeting Agenda
The November 2018 PBAC Meeting is scheduled to conclude today. Here, the Commercial Eyes Market Access team provides an analysis of the meeting agenda, including Sponsors with multiple submissions and the nature of requested listings by type. The … Continue reading
PBAC Meeting Outcomes – July 2018
The July 2018 PBAC Meeting Outcomes were published on 17th August 2018. With 64 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including additional analysis conducted on biosimilar and oncology submissions. … Continue reading
Public Submissions to the August 2018 PBAC Special Meeting – Part 2
In the second part of this two-part series (Read Part 1 about here) we bring you further insight into opinions from the public submissions to the August 2018 PBAC Special Meeting. Opinions from the Public Submissions Outcomes of the PBAC’s … Continue reading
Sponsors struggle with Ministerial discretion
The 2017 Medicines Australia Strategic Agreement with the Australian Government extended the existing five-year anniversary statutory price reduction (SPR) of 5% for F1 medicines and introduced new SPRs for drugs that have been listed for ten years and fifteen years … Continue reading
